CA19-9、CA242和CA50联检对胰腺癌诊断的价值  

Diagnostic Value of Combined Determinations of Serum CA19-9,CA242 and CA50 Levels in Patients with Pancreatic Cancer

作　　者：易丹[1] 殷跃[1] 

机构地区：[1]湖南省人民医院核医学科,410005

出　　处：《放射免疫学杂志》2009年第4期328-330,共3页Journal of Radioimmanology

摘　　要：目的:探讨联检肿瘤标志物CA19-9、CA242和CA50在胰腺癌诊断中的应用价值。方法:选择2007年1月～2008年10月湖南省人民医院门诊及住院患者共250人进行了CA19-9、CA242和CA50联检,其中120例为临床明确诊断的胰腺癌患者。结果:胰腺癌患者血清中的CA19-9、CA242和CA50水平明显高于对照组。CA19-9敏感性和特异性分别为82.0%和79.6%;CA242敏感性和特异性分别为78.5%和81.6%;CA50敏感性和特异性分别为52.7%和74.6%;联检CA19-9、CA242和CA50其敏感性和特异性提高为96.82%和98.75%。结论:采用CA19-9、CA242和CA50联检的方法,对胰腺癌的早期诊断具有一定的临床意义。Objective To explore the diagnostic value of combined determinations of serum CA19-9,CA242 and CA50 levels in patients with pancreatic cancer.Methods Serum CA19-9,CA242 and CA50 levels were determined with RIA in 120 patients with pancreatic cancer,50 patients with chronic pancreatitis and 80 controls.Results The serum levels of CA19-9,CA242 and CA50 in patients with pancreatic cancer were significantly higher than those in patients with pancreatitis and controls.With CA19-9,the diagnostic sensitivity and specificity for pancreatic cnrcinoma was 82.0% and 78.6% respectively.With CA242,the diagnostic sensitivity and specificity for pancreatic carcinoma was 78.5% and 81.6% respectively.With CA50,the diagnostic sensitivity and specificity for pancreatic carcinoma was 52.7% and 74.6% respectively.With combined determinations of CA19-9,CA242 and CA50,the sensitivity and specificity was enhanced to 96.82% and 98.75% respectively.Conclusion Combined detection of CA19-9,CA242 and CA50 is clinically useful for early diagnosis of pancreatic cancer.

关 键 词：胰腺癌 肿瘤标志物 敏感性 联合检测 

分 类 号：R735.04[医药卫生—肿瘤] R735.9[医药卫生—临床医学]